Cite
Mesenchymal tumor cells drive adaptive resistance of Trp53-/- breast tumor cells to inactivated mutant Kras.
MLA
van Weele, Linda J., et al. “Mesenchymal Tumor Cells Drive Adaptive Resistance of Trp53-/- Breast Tumor Cells to Inactivated Mutant Kras.” Molecular Oncology, vol. 16, no. 17, Sept. 2022, pp. 3128–45. EBSCOhost, https://doi.org/10.1002/1878-0261.13220.
APA
van Weele, L. J., Djomehri, S. I., Cai, S., Antony, J., Sikandar, S. S., Qian, D., Ho, W. H. D., West, R. B., Scheeren, F. A., & Clarke, M. F. (2022). Mesenchymal tumor cells drive adaptive resistance of Trp53-/- breast tumor cells to inactivated mutant Kras. Molecular Oncology, 16(17), 3128–3145. https://doi.org/10.1002/1878-0261.13220
Chicago
van Weele, Linda J., Sabra I. Djomehri, Shang Cai, Jane Antony, Shaheen S. Sikandar, Dalong Qian, William H. D. Ho, Robert B. West, Ferenc A. Scheeren, and Michael F. Clarke. 2022. “Mesenchymal Tumor Cells Drive Adaptive Resistance of Trp53-/- Breast Tumor Cells to Inactivated Mutant Kras.” Molecular Oncology 16 (17): 3128–45. doi:10.1002/1878-0261.13220.